Semaglutide
GLP-1 receptor agonist
GLP-1 receptor agonist with approved prescription products and extensive randomized human evidence across diabetes, obesity and cardiovascular-risk reduction.
Reference dose
0.25 mg weekly start; maintenance 0.5–2.4 mg weekly, up to 7.2 mg for certain adults
Source-specific educational reference, not an individualized recommendation.
Reference schedule
Once-weekly injection; approved oral formulations are taken once daily
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
Drug class
GLP-1 receptor agonist
A well-characterized incretin-based prescription medicine.
Evidence base
Large human RCTs
Extensive randomized clinical programmes across multiple indications.
Regulatory status
Approved products
Approval and dosing are product- and indication-specific.
Formats
Injection + oral
Commercial formulations use different devices and instructions.
What it is
Semaglutide is a long-acting GLP-1 receptor agonist developed as a prescription medicine for metabolic disease.
It is the active ingredient in multiple approved products, including injectable and oral formulations, with indications that depend on the specific brand and jurisdiction.
Research focus
How it works
Semaglutide activates the GLP-1 receptor, increasing glucose-dependent insulin signalling, reducing glucagon when appropriate, slowing gastric emptying and affecting appetite and energy intake.
Important context
Semaglutide is one molecule used in multiple prescription products with different indications, strengths, devices and dosing instructions. A profile should not collapse Ozempic, Wegovy and oral semaglutide into one interchangeable dose chart.
What it is studied for
Obesity and weight-management research examines appetite, energy intake, body weight and obesity-related outcomes.
Diabetes research examines glucose control and cardiometabolic risk in people with type 2 diabetes.
Large outcomes programmes have extended the evidence base into cardiovascular and kidney outcomes in specifically defined patient populations.
More contextWhy brand, indication and device matterSee the deeper context, evidence details and practical distinctions behind this profile.
Semaglutide has a much stronger evidence base than investigational peptides, including large randomized trials and FDA-approved indications. That also means the safest reference is the current product label rather than informal click-counting or peptide-vial conventions.
FDA has continued to update semaglutide labels and indications. In 2024 Wegovy gained a cardiovascular-risk-reduction indication in a defined population, and in March 2026 FDA approved a higher-dose 7.2 mg Wegovy HD presentation for certain adults.
- Ozempic is an approved semaglutide injection for type 2 diabetes with additional labelled cardiovascular and kidney-risk-reduction indications in defined populations.
- Wegovy is an approved semaglutide product for chronic weight management and has additional cardiovascular-risk-reduction labeling for defined adults with cardiovascular disease and overweight or obesity.
- The approved pens are engineered delivery devices. Their labelled instructions should take priority over generic pen-click arithmetic.
- Compounded semaglutide is not FDA-approved and should not be described as automatically equivalent to an approved branded product.
Why people are interested
What makes Semaglutide worth researching.
Large randomized human trials
Weight management
Large randomized trials show clinically meaningful weight reduction with once-weekly semaglutide in adults with overweight or obesity when used under studied treatment programmes.
Approved + extensive human evidence
Type 2 diabetes
Semaglutide has established glucose-lowering efficacy and approved products for type 2 diabetes.
Outcome trial + FDA-approved indication
Cardiovascular outcomes
Wegovy has an FDA-approved indication to reduce major cardiovascular events in defined adults with cardiovascular disease and overweight or obesity.
Approved indication
Kidney outcomes
Current Ozempic labeling includes reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in defined adults with type 2 diabetes and chronic kidney disease.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
Human · large randomized trials
Obesity
STEP 1 and subsequent studies established substantial weight reduction with weekly semaglutide compared with placebo in defined populations receiving lifestyle intervention.
Human outcomes · approved
Cardiovascular risk
FDA approved Wegovy for cardiovascular-risk reduction in a defined population after a large outcomes trial showed fewer major adverse cardiovascular events than placebo.
Large clinical-development database
Safety profile
Gastrointestinal effects are common. Labels also address pancreatitis, gallbladder disease, kidney injury related to volume depletion, retinopathy complications in some diabetes settings and other clinically important precautions.
Approved prescribing labels
Product-specific dosing
Ozempic, Wegovy and oral semaglutide products have different strengths, indications and instructions. The active ingredient does not make the devices or dose schedules interchangeable.
Human research
Semaglutide has one of the deepest human evidence bases in this library, including large randomized programmes in type 2 diabetes and obesity.
In STEP 1, once-weekly semaglutide 2.4 mg plus lifestyle intervention produced substantially greater weight reduction than placebo over 68 weeks in adults with overweight or obesity without diabetes.
A large cardiovascular outcomes programme supported FDA's 2024 Wegovy indication to reduce cardiovascular death, heart attack and stroke in adults with cardiovascular disease and overweight or obesity.
Current FDA labeling for Ozempic also includes specific cardiovascular and kidney-risk-reduction indications in adults with type 2 diabetes who meet the labelled criteria.
Preclinical research
Preclinical pharmacology helped define GLP-1 receptor effects, but clinical use and benefit-risk assessment are supported primarily by extensive human trial and post-approval evidence.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
0.25 mg weekly start; maintenance 0.5–2.4 mg weekly, up to 7.2 mg for certain adults
Once-weekly injection; approved oral formulations are taken once daily
Use the current prescribing information for the specific semaglutide product and indication. This profile intentionally avoids turning several different approved labels into one simplified universal dose ladder.
Calculator connection
This profile does not currently use a vial or pen calculator. Follow the formulation-specific information shown for the product or reference you are using.
Approved semaglutide pens and tablets are product-specific. Do not infer a dose by treating a fixed-dose or manufacturer-designed pen like a generic research-peptide click pen.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Rule of thumb only: storage belongs to the exact finished formulation, not simply to the name semaglutide. Use the label or validated pharmacy/manufacturer instructions for the product in hand.
Pen rule of thumb
For finished pens, think label-first: keep the device protected from heat and light, do not freeze it, and follow that exact pen's unopened and in-use temperature window. Different semaglutide pens have different in-use rules.
Vial rule of thumb
For compounded or research vials, treat dry and reconstituted material as different stability states. Refrigeration after mixing may be specified for some products, but there is no universal semaglutide vial rule.
Known data
For semaglutide, the strongest storage data comes from approved products with validated labeling. Current Wegovy labeling stores single-dose pens or syringes refrigerated at 2–8°C (36–46°F); before cap removal they may be kept at 8–30°C (46–86°F) for up to 28 days, protected from light and never frozen.
For semaglutide, approved multidose pens can have different in-use conditions. Current Ozempic labeling allows an in-use pen to be kept for 56 days either refrigerated at 2–8°C or at controlled room temperature of 15–30°C (59–86°F), with protection from excessive heat and sunlight.
Formulation context
For semaglutide, formulation context matters because those storage periods were validated for finished products with specific buffers, preservatives, containers and delivery systems. A Wegovy pen, an Ozempic pen, a compounded vial and a lyophilized research vial are not interchangeable stability systems.
For semaglutide, reconstitution creates a separate stability question. Diluent, concentration, preservative system, container closure, sterility and handling can all change the usable storage window.
What is not established
For semaglutide, what remains unestablished is a universal post-reconstitution shelf life that applies to every compounded or research vial. A claim such as 'stable for X weeks after mixing' needs evidence for that exact formulation rather than being borrowed from an approved pen.
For semaglutide, product-specific storage instructions should therefore be distinguished from supplier claims that are not supported by formulation-specific stability data.
Sources
The sources below support the product-specific storage distinctions above.
Practical reference
Formats
Prefilled injection pen
Oral tablet
Reconstitution & units
FDA-approved semaglutide pens are supplied as finished prescription products and should not be treated like lyophilized research vials requiring user reconstitution.
Follow the labelled dose and device instructions for the specific product.
This profile intentionally disables the generic pen calculator because manufacturer-designed semaglutide devices should not be reverse-engineered through informal click counting.
Safety, status & open questionsOpen the practical cautionsSemaglutide is an established prescription medicine, but approval applies to specific products, strengths, routes and indications. The active ingredient being approved does not make every semaglutide-containing product an approved equivalent.
Open questions
Results from one product, dose or study population should not automatically be generalized to every semaglutide formulation or every person.
The optimal product and dose depend on the approved indication, medical history, tolerability and clinical context.
Compounded semaglutide products do not automatically share the quality, device performance or approval status of FDA-approved products.
Regulatory notes
FDA-approved semaglutide products exist for defined indications, including type 2 diabetes and chronic weight management.
In 2024 FDA approved a Wegovy cardiovascular-risk-reduction indication for defined adults with cardiovascular disease and overweight or obesity.
In March 2026 FDA approved Wegovy HD 7.2 mg for weight loss and long-term weight maintenance in certain adults.
Compounded semaglutide products are not FDA-approved products and are not reviewed by FDA for safety, effectiveness or quality before marketing.
Practical notes
Common adverse effects include nausea, vomiting, diarrhoea, abdominal pain and constipation.
Current labels include warnings or precautions for pancreatitis, gallbladder disease, kidney injury related to volume depletion, severe gastrointestinal reactions and other clinically important risks.
Ozempic and Wegovy labeling includes a boxed warning regarding thyroid C-cell tumors observed in rodents and contraindications involving medullary thyroid carcinoma or MEN 2.
GLP-1 receptor agonists delay gastric emptying, which can matter for oral medicines and for procedures involving anesthesia or deep sedation.
Common mistakes
Treating Ozempic, Wegovy and oral semaglutide as the same product with interchangeable doses.
Trying to calculate an approved fixed-dose or manufacturer-designed pen by generic click-count rules.
Assuming a compounded semaglutide product is FDA-approved because semaglutide itself is an approved active ingredient.
Comparing weight-loss percentages across trials without accounting for dose, population, duration and trial design.
Common questions
Are Ozempic and Wegovy the same thing?
They contain semaglutide, but they are distinct prescription products with different approved indications, strengths and dosing instructions.
Does semaglutide have strong human evidence?
Yes. It has extensive randomized clinical-trial evidence and approved indications, making it very different evidentially from most investigational peptides on this site.
Why is the generic pen calculator disabled here?
Approved semaglutide devices should be used according to their product-specific instructions. Informal click counting can misrepresent how a particular pen is designed to deliver medication.
Is compounded semaglutide the same as an FDA-approved product?
No. Compounded drugs are not FDA approved and FDA does not review them for safety, effectiveness or quality before marketing.
Related peptides & blends
References
Ozempic prescribing information — revised May 2026
U.S. FDA / Drugs@FDA · 2026
FDA approval — Wegovy cardiovascular risk reduction
U.S. FDA · 2024
FDA approval — Wegovy HD 7.2 mg
U.S. FDA · 2026
STEP 1 — once-weekly semaglutide in adults with overweight or obesity
New England Journal of Medicine / PubMed · 2021
FDA — understanding the risks of compounded drugs
U.S. FDA · 2026